Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310805 | 0.89 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL1814622 | 0.89 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL16824869 | 0.88 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL16825024 | 0.88 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSMN1; SMN2MET | |
| SCHEMBL31121072 | 0.88 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL23887582 | 0.87 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTSMN1; SMN2MET | |
| SCHEMBL30114934 | 0.87 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTSMN1; SMN2MET | |
| SCHEMBL23887626 | 0.87 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL30114964 | 0.87 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL25404203 | 0.85 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | ALDH1A1 1940/4885LMNA 3631/4885MAPT 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.